Live
FierceBiotechRare Disease Research, myTomorrows team up to help patients access trialsFierceBiotechAligos sells China rights to HBV drug to hepatology player Amoytop in $445M dealFierceBiotechPfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trialFierceBiotechJohnson & Johnson hands back failed eye disease gene therapy to MeiraGTxFierceBiotech'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once againThermo FisherThermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy? - Yahoo FinancePromega BlogStolen Chloroplasts and the Chrysalis of Complex LifeIlluminaDRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows - PR NewswireLonza NewsKeyBanc reiterates Lonza stock rating on strong modality positioning By Investing.com - Investing.com CanadaBioWorldPerha Pharmaceuticals identifies new adenosine A3 receptor antagonistsBioWorldCogent Biosciences identifies new JAK2 V617F inhibitorsBioWorldCorbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists
FierceBiotech Apr 16, 2026

Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial

Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial

Original
Body unavailable. Use the original source.